GlassScriptPhysician profile
Lowell Frederick Clark
NPI 1336103563
$1,251.16
in general payments reported to CMS, 2019-2025
24 companies · $22.02 in 2025
The $22.02 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $165 · 2021: $168 · 2022: $112 · 2023: $154 · 2025: $22.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $203.50 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $121.83 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $115.78 | 2019 | |
| Amgen INC. | $102.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $95.71 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $78.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.16 | 2019-2020 | |
| Esperion Therapeutics, INC. | $61.70 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $44.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $40.50 | 2020-2022 | |
| Vivus LLC | $38.92 | 2021 | |
| Ucb, INC. | $37.73 | 2019 | |
| Glaxosmithkline, LLC. | $33.32 | 2019 | |
| Pfizer INC. | $26.53 | 2022-2023 | |
| Amarin Pharma, INC. | $25.08 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $23.76 | 2021 | |
| Abbott Laboratories | $22.31 | 2022 | |
| Acadia Pharmaceuticals INC | $22.02 | 2025 | Nuplazid |
| Exact Sciences Corporation | $18.54 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $17.28 | 2021 | |
| Radius Health, INC. | $14.53 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.32 | 2022 | |
| Neurelis, INC. | $12.38 | 2022 | |
| Ethicon US, LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.